Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Alnara Pharmaceuticals have signed a definitive merger agreement whereby Eli Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases.
Subscribe to our email newsletter
Alnara Pharma’s product Liprotamase is an oral, non-porcine pancreatic enzyme replacement therapy (PERT) designed to treat maldigestion, malabsorption and malnutrition as a result of exocrine pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic diseases.
Liprotamase is under review by the FDA for the treatment of exocrine pancreatic insufficiency (EPI).
Bryce Carmine, executive vice president of Lilly and president of Lilly BioMedicines, said: “The acquisition of Alnara provides Lilly with a entry into enzyme replacement therapy, an area with unmet medical needs as well as opportunities for new compounds. We look forward to partnering with Alnara’s experts during the regulatory review process of Liprotamase.”
Alexey Margolin, CEO of Alnara, said: “Our agreement with Lilly is an important development as we move Liprotamase through FDA regulatory review. We look forward to finalising the transaction and working together on next steps to bring Liprotamase to patients.”
The transaction under the merger is contingent upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.